DTI Therapeutic Programs
At DTI, we are developing treatments for a broad range of indications in the lung. Beyond the lung cancers, we have begun novel target discovery and validation by directly probing genetic loci that come from GWAS studies of common diseases, such as COPD and asthma. We are using localized epigenetic remodeling to treat these indications and also devising therapeutic strategies for metastatic liver diseases such as uveal melanoma.
DTI Genomic Medicine Platform
Our mission is to build and expand our drug discovery platform to realize the potential of the technology and revolutionize medicine in areas where there have never been effective and safe treatments. The platform is a ground-breaking combination and integration of tools for protein and nucleic acid structural biology with genomics, molecular biology, bioinformatics, statistical genetics and machine learning to deliver a custom-designed macromolecular therapeutic to a specific locus in the genome.
Contact Us
We’re looking for new opportunities to collaborate with commercial, academic and non-profit organizations. Please provide a short description of the potential opportunity and we will contact you shortly to discuss next steps.